Ovid Therapeutics Inc (NASDAQ: OVID) kicked off on Friday, up 15.43% from the previous trading day, before settling in for the closing price of $0.84. Over the past 52 weeks, OVID has traded in a range of $0.24-$1.47.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 24.72% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -38.22%. With a float of $59.51 million, this company’s outstanding shares have now reached $71.11 million.
In an organization with 23 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 98.51%, operating margin of -625.03%, and the pretax margin is -574.02%.
Ovid Therapeutics Inc (OVID) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Ovid Therapeutics Inc is 16.32%, while institutional ownership is 34.63%. The most recent insider transaction that took place on Feb 26 ’25, was worth 2,956. In this transaction President and COO of this company sold 5,279 shares at a rate of $0.56, taking the stock ownership to the 73,406 shares. Before that another transaction happened on Feb 26 ’25, when Company’s CBFO sold 3,902 for $0.56, making the entire transaction worth $2,185. This insider now owns 67,973 shares in total.
Ovid Therapeutics Inc (OVID) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.2 earnings per share (EPS), higher than consensus estimate (set at -0.23) by 0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.13 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -38.22% per share during the next fiscal year.
Ovid Therapeutics Inc (NASDAQ: OVID) Trading Performance Indicators
Take a look at Ovid Therapeutics Inc’s (OVID) current performance indicators. Last quarter, stock had a quick ratio of 4.72. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.37.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.54, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.57 in one year’s time.
Technical Analysis of Ovid Therapeutics Inc (OVID)
Let’s dig in a bit further. During the last 5-days, its volume was 3.53 million. That was better than the volume of 0.97 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 93.64%.
During the past 100 days, Ovid Therapeutics Inc’s (OVID) raw stochastic average was set at 93.57%, which indicates a significant increase from 90.83% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0748 in the past 14 days, which was higher than the 0.0428 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.4528, while its 200-day Moving Average is $0.6132. However, in the short run, Ovid Therapeutics Inc’s stock first resistance to watch stands at $1.0565. Second resistance stands at $1.1429. The third major resistance level sits at $1.2659. If the price goes on to break the first support level at $0.8471, it is likely to go to the next support level at $0.7241. Assuming the price breaks the second support level, the third support level stands at $0.6377.
Ovid Therapeutics Inc (NASDAQ: OVID) Key Stats
The company with the Market Capitalisation of 68.98 million has total of 71,110K Shares Outstanding. Its annual sales at the moment are 570 K in contrast with the sum of -26,430 K annual income. Company’s last quarter sales were recorded 130 K and last quarter income was -10,240 K.
